Tubigon, Jesse .
HRN: 25-94-93 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/09/2024
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
10/09/2024
10/15/2024
IVTT
500 Mg
OD
Cellulitis, Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes